ADMA Biologics, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:ADMA
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 749 out of 909
Universe
Global Universe 13496 out of 16009
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Twist Bioscience Corp. |
25.5
Medium
|
243 out of 909 |
Rhythm Pharmaceuticals, Inc. |
25.7
Medium
|
259 out of 909 |
Walvax Biotechnology Co., Ltd. |
26.9
Medium
|
333 out of 909 |
Geron Corp. |
27.9
Medium
|
408 out of 909 |
ADMA Biologics, Inc. |
34.8
High
|
749 out of 909 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
ADMA Biologics, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
ADMA Biologics, Inc.'s Management of ESG Material Risk is Weak
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted ADMA Biologics, Inc.'s ESG Risk Rating in the last three years
Highest Controversy Level
![blurred controversy level](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-level-blur.jpg)
Contributing Events
![blurred controversy events](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-events-blur.jpg)
Highest Controversy Events Locations
![world map blurred](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-events-map-blur.jpg)